These results indicate that it is very worthwhile to explore the mechanism of TME orchestration caused by HOXC6 upregulation, which is expected to provide a candidate biomarker for CRC adjuvant immunotherapy cohort screening. The gene discussed is HOXC6; the disease is colorectal carcinoma.